Ticker Details
Merus N.V. Merus NV is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics.
IPO Date:	May 19, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$7.22B
Activated in VL:	False

Average Daily Range
Avg Daily Range:	$0.62 | 2.71%
Avg Daily Range (30 D):	$0.20 | 0.21%
Avg Daily Range (90 D):	$0.75 | 1.15%

Institutional Daily Volume
Avg Daily Volume:	.28M
Avg Daily Volume (30 D):	3.63M
Avg Daily Volume (90 D):	1.6M

Trade Size
Avg Trade Size (Sh.):	88
Avg Trade Size (Sh.) (30 D):	145
Avg Trade Size (Sh.) (90 D):	106

Institutional Trades
Total Institutional Trades:	2,990
Avg Institutional Trade:	$2.38M
Avg Institutional Trade (30 D):	$4.22M
Avg Institutional Trade (90 D):	$3.78M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$2.53M
Avg Closing Trade (30 D):	$7.33M
Avg Closing Trade (90 D):	$4.96M
Avg Closing Volume:	50.34K

News

Dec 16, 2025 @ 6:17 PM Immunotherapy Breakthroughs Turn Cold GI Tumors Ho... Source: Prnewswire

Dec 12, 2025 @ 6:35 AM Genmab Announces Completion of Tender Offer for Ou... Source: Genmab A/S

Dec 3, 2025 @ 8:03 PM Genmab Announces Closing of Private Offering of Se... Source: Genmab A/S

Nov 22, 2025 @ 11:25 AM Halper Sadeh LLC Encourages EXAS, NVRI, MRUS Share... Source: Halper Sadeh Llc

Oct 25, 2025 @ 9:24 AM Tussentijdse gegevens van Merus over petosemtamab ... Source: Merus N.V.

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS		$-1.26	$-2.23
Diluted EPS		$-1.26	$-2.23
Revenue		$12.15M	$8.83M
Gross Profit
Net Income / Loss		$-95.52M	$-158.22M
Operating Income / Loss		$-96.48M	$-110.35M
Cost of Revenue
Net Cash Flow		$-75.3M	$245.63M
PE Ratio